In the investigation for CAFs and CD8+ or forkhead box protein 3 tumor-infiltrating lymphocytes by IHC, it was revealed that IL-6 blockade, or targeting CAFs, may improve preexisting tumor immunity and enhance the efficacy of conventional immunotherapies [92]. This evidence concerns the gene CD8A and neoplasm.